Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 6Phase 3 5Phase NA 4Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 108Thoracic 89Other hematologic neoplasm 87Genitourinary 86Lymphoid 84Other solid neoplasm 74Breast 60Gynecologic 51CNS 49Tumor-Agnostic 43Sarcoma 41Head & Neck 37Plasma cell 36Dermatologic 34Myeloid 32Endocrine 10Classical hematology 4NET 2Other 1

Conditions

Neuroendocrine Tumors 2

Interventions

lutetium Lu 177 dotatate 2Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Specimen Handling 1Single Photon Emission Computed Tomography Computed Tomography 1Positron Emission Tomography Computed Tomography 1Magnetic Resonance Spectroscopy 164Cu-DOTATATE 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × NET × 30 days × Clear all
NCT04234568 2026-06-01

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
31 enrolled 16 charts
EndocrineNET

Neuroendocrine Tumors

NCT06122610 2026-05-15

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

University of Wisconsin, Madison

Phase 1 Recruiting
10 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡